House Democrats contend the $15 per hour minimum wage bill will lift workers who have not seen the benefits of a strong economy.Politicsread more
The Philadelphia Fed saw its primary gauge measuring the sector jump from 0.3 in June to 21.8, far better than Wall Street estimates of 5 and the highest in a year.Economyread more
Stocks erased earlier losses, but the rise was kept in check as Wall Street digested a mixed batch of corporate earnings results.US Marketsread more
"It's better to take preventative measures than to wait for disaster to unfold," Williams told the annual meeting of the Central Bank Research Association.The Fedread more
The fact that interest rates are relatively low makes the idea of a so-called insurance rate cut later this month an attractive option for the Fed.Market Insiderread more
Video of the event does not show the president disagreeing with his supporters. Instead, it shows that Trump paused as the chant began, allowing his supporters to continue...Politicsread more
President Trump said he's looking at the JEDI Contract that will be awarded to Microsoft or Amazon.Technologyread more
Hacker Square at Facebook's headquarters pays homage to the company's early motto of moving fast and breaking things.Technologyread more
It's tempting to view Netflix as a possible replacement for the entire media ecosystem. But execs on its Q2 earnings call showed lower ambitions: It just wants to create the...Technologyread more
These are the stocks posting the largest moves midday.Market Insiderread more
Jeffrey Epstein, a former friend of Presidents Donald Trump and Bill Clinton, had asked a judge to release him on a bond of as high as $100 million or more.Politicsread more
Eli Lilly reported better-than-expected quarterly sales, driven by demand for its newer treatments for diabetes and cancer.
Shares of the drugmaker were up 1 percent before the opening bell.
Revenue rose 8.6 percent to $5.4 billion in the second quarter, topping Wall Street estimates of $5.15 billion, as demand increased for its drugs including Trulicity, Cyramza and Humalog.
"We're pleased with revenue this quarter," CEO John Lechleiter told CNBC's "Squawk Box."
"I think it's important 8 percent of that is volume growth. Six percentage points came from new products we've launch since 2014, so this is exactly the trajectory we want to be on," he said.
Lilly resumed earnings growth last year after three years of tumbling sales due to weak demand for its key products amid competition from generic products.
The 140-year-old U.S. drugmaker said its net income rose 24.5 percent to $747.7 million, or 71 cents per share, in the quarter ended June 30.
Excluding special items, Lilly earned 86 cents per share, in line with the average analyst estimate, according to Thomson Reuters.
— CNBC's Tom DiChristopher contributed to this report.